bluuebunny/crossref_metadata_2025 huggingface dataset:
Table S1 from Radiosensitization In Vivo by Histone Deacetylase Inhibition with No Increase in Early Normal Tissue Radiation Toxicity
Authors: Groselj Blaz , Ruan Jia-Ling , Scott Helen , Gorrill Jessica , Nicholson Judith , Kelly Jacqueline , Anbalagan Selvakumar , Thompson James , Stratford Michael R.L. , Jevons Sarah J. , Hammond Ester M. , Scudamore Cheryl L. , Kerr Martin , Kiltie Anne E.
Published: April 2023

List of primers and antibodies.
Supplementary Tables 1-3, Figures 1-3, and Supplementary Materials and Methods from Pharmacologic Inhibition of the Menin–MLL Interaction Leads to Transcriptional Repression of PEG10 and Blocks Hepatocellular Carcinoma
Authors: Kempinska Katarzyna , Malik Bhavna , Borkin Dmitry , Klossowski Szymon , Shukla Shirish , Miao Hongzhi , Wang Jingya , Cierpicki Tomasz , Grembecka Jolanta
Published: April 2023

Supplementary Figure 1. Expression of menin, MLL1 and MLL2 in HCC cell lines; Supplementary Figure 2. MI-503 affects cell migration in HCC cell lines; Supplementary Figure 3. MI-503 does not induce toxicity in mice; Supplementary Table 1. Inhibition of cell viability in HCC cell lines by menin-MLL inhibitors; Supplementary Table 2. RNAseq data from MI-503 treatment in HepG2 cells; Supplementary Table 3. Mutation status of CTNNB1 in human HCC cell lines
Table S2 from Impact of the Anticancer Drug NT157 on Tyrosine Kinase Signaling Networks
Authors: Su Shih-Ping , Flashner-Abramson Efrat , Klein Shoshana , Gal Mor , Lee Rachel S. , Wu Jianmin , Levitzki Alexander , Daly Roger J.
Published: April 2023

Summary of kinase panel used for testing of NT157 activity.
Tables S1-S5; Figures S1-S5 from Development of MGD007, a gpA33 x CD3-Bispecific DART Protein for T-Cell Immunotherapy of Metastatic Colorectal Cancer
Authors: Moore Paul A. , Shah Kalpana , Yang Yinhua , Alderson Ralph , Roberts Penny , Long Vatana , Liu Daorong , Li Jonathan C. , Burke Steve , Ciccarone Valentina , Li Hua , Fieger Claudia B. , Hooley Jeff , Easton Ann , Licea Monica , Gorlatov Sergey , King Kathy L. , Young Peter , Adami Arash , Loo Deryk , Chichili Gurunadh R. , Liu Liqin , Smith Douglas H. , Brown Jennifer G. , Chen Francine Z. , Koenig Scott , Mather Jennie , Bonvini Ezio , Johnson Syd
Published: April 2023

Supplementary Table 1: Sixteen-locus STR analysis of tumor tissue and banked CSLC lines Supplementary Table 2: CSLC derivation and characteristics Supplementary Table 3: Immunohistochemical Analysis of Colorectal Cancer Tumor Specimens Supplementary Table 4: Equilibrium Dissociation Constants (KD) for Binding of MGD007 to Human CD3 or gpA33 Supplementary Table 5: MGD007 Pharmacokinetic Parameters Derived from Two-compartment Analysis in Cynomolgus Monkeys Supplementary Figure 1: In vitro CSLC differentiation in MatrigelTM 3D cultures Supplementary Figure 2: RECA47 mAb binding restricted to intestinal epithelium Supplementary Figure 3: MGD007 Flow Cytometry Analyses on Tumor Cell Lines Supplementary Figure 4: Expanded Treg population exhibits suppressive T-cell properties Supplementary Figure 5: Cytokine Levels in Monkeys Following Treatment with MGD007
Supplementary Figures 1-5 and Supplmentary Materials and Methods. from Inhibition of Copper Transport Induces Apoptosis in Triple-Negative Breast Cancer Cells and Suppresses Tumor Angiogenesis
Authors: Karginova Olga , Weekley Claire M. , Raoul Akila , Alsayed Alhareth , Wu Tong , Lee Steve Seung-Young , He Chuan , Olopade Olufunmilayo I.
Published: April 2023

Figure S1 - Western blot images showing ATOX1 and CCS levels in TNBC cells, corresponding to data presented in Figure 1. Figure S2 - Dose-response profiles of TM in TNBC cells and DCAC50 in HMEC; caspase-3/7 activity after DCAC50 treatment of HMEC. Figure S3 - Copper content, copper distribution and iron and zinc content for DCAC50-treated TNBC cells, supplementing Figure 3. Figure S4 - Protein levels of copper transporters, GSH levels, GSH depletion experiments and SOD1 activity levels in TNBC cells in response to DCAC50 treatment, supplementing Figure 4. Figure S5 - Dose-response profile for DCAC50 and caspase-3/7 activity after DCAC50 treatment in HuVEC. Figure S6 - Evaluation of DCAC50 treatment on tumor volumes and angiogenesis in MDA-MB-468 and MDA-MB-231 xenograft mouse models, supplementing Figure 5. Supplementary Methods ¬- Information about the antibodies and detailed procedures used for Western blot, immunofluorescent staining and SOD activity assay.
Supplementary Table S5 from Preclinical Development of a Bispecific Antibody that Safely and Effectively Targets CD19 and CD47 for the Treatment of B-Cell Lymphoma and Leukemia
Authors: Buatois Vanessa , Johnson Zoë , Salgado-Pires Susana , Papaioannou Anne , Hatterer Eric , Chauchet Xavier , Richard Françoise , Barba Leticia , Daubeuf Bruno , Cons Laura , Broyer Lucile , D'Asaro Matilde , Matthes Thomas , LeGallou Simon , Fest Thierry , Tarte Karin , Clarke Hinojosa Robert K. , Genescà Ferrer Eulàlia , Ribera José María , Dey Aditi , Bailey Katharine , Fielding Adele K. , Eissenberg Linda , Ritchey Julie , Rettig Michael , DiPersio John F. , Kosco-Vilbois Marie H. , Masternak Krzysztof , Fischer Nicolas , Shang Limin , Ferlin Walter G.
Published: April 2023

Supplementary Table S5 shows the hematological results of cynomolgus monkeys treated with vehicle (Ctr.) or NI-1701 (Treat.) at 30 and 100 mg/kg over 4 weeks.
Supplementary Tables 1-3. Supplmentary Figure 1-5. from ST8SIA1 Regulates Tumor Growth and Metastasis in TNBC by Activating the FAK–AKT–mTOR Signaling Pathway
Authors: Nguyen Khoa , Yan Yuanqing , Yuan Bin , Dasgupta Abhishek , Sun Jeffrey , Mu Hong , Do Kim-Anh , Ueno Naoto T. , Andreeff Michael , Battula V. Lokesh
Published: April 2023

Supplementary Table 1. Signaling pathways downregulated in ST8SIA1-knockout cells. GSEA analysis was performed using genes that were differentially expressed in Cas9-Control and ST8SIA1-KO cells (Fig 4A). Supplementary Table 2. Proteomic analysis of GD2+ and GD2- SUM159 cells. GD2+ and GD2-SUM159 cells FACS-sorted as shown in Fig 5A, protein expression and phosphorylation was examined by Kinexus antibody array. Supplementary Table 3. Antibodies used in the western blot analysis. Supplementary Figure 1. ST8SIA1 mRNA expression in breast cancer cell lines. Supplementary Figure 2. Correlation of gene expression with ST8SIA1 expression in primary breast tumors. Supplementary Figure 3. DNA sequencing to determine the genomic alteration made by CRISPR-Cas9 in the ST8SIA1 gene. Supplementary Figure 4. Characterization of ST8SIA1-KO TNBC cells. Supplementary Figure 5. Knockout of ST8SIA1 inhibits BCSC function in vitro.
Supplementary materials and methods from The Unfolded Protein Response: A Novel Therapeutic Target for Poor Prognostic BRAF Mutant Colorectal Cancer
Authors: Forsythe Nicholas , Refaat Alaa , Javadi Arman , Khawaja Hajrah , Weir Jessica-Anne , Emam Heba , Allen Wendy L. , Burkamp Frank , Popovici Vlad , Jithesh Puthen V. , Isella Claudio , Labonte Melissa J. , Mills Ian G. , Johnston Patrick G. , Van Schaeybroeck Sandra
Published: April 2023

Supplementary materials and methods
Supplementary Figure 3 from RON Receptor Tyrosine Kinase as a Therapeutic Target for Eradication of Triple-Negative Breast Cancer: Efficacy of Anti-RON ADC Zt/g4-MMAE
Authors: Suthe Sreedhar Reddy , Yao Hang-Ping , Weng Tian-Hao , Hu Chen-Yu , Feng Liang , Wu Zhi-Gang , Wang Ming-Hai
Published: April 2023

Fig. S3 is about the detection of spontaneous activation of RON in TNBC cell lines
Supplemental figure 1 from Molecularly Targeted Cancer Combination Therapy with Near-Infrared Photoimmunotherapy and Near-Infrared Photorelease with Duocarmycin–Antibody Conjugate
Authors: Nagaya Tadanobu , Gorka Alexander P. , Nani Roger R. , Okuyama Shuhei , Ogata Fusa , Maruoka Yasuhiro , Choyke Peter L. , Schnermann Martin J. , Kobayashi Hisataka
Published: April 2023

Absorbance spectra of both Ab-conjugates for additional QC
Supplementary Methods from Combined Inhibition of PI3Kβ and mTOR Inhibits Growth of PTEN-null Tumors
Authors: Lynch James T. , Polanska Urszula M. , Hancox Ursula , Delpuech Oona , Maynard Juliana , Trigwell Catherine , Eberlein Catherine , Lenaghan Carol , Polanski Radoslaw , Avivar-Valderas Alvaro , Cumberbatch Marie , Klinowska Teresa , Critchlow Susan E. , Cruzalegui Francisco , Barry Simon T.
Published: April 2023

Supplementary methods for in vivo studies
Supplemental Figure 3 from Short- and Long-Term Effects of CDK4/6 Inhibition on Early-Stage Breast Cancer
Authors: Kietzman William B. , Graham Garrett T. , Ory Virginie , Sharif Ghada M. , Kushner Max H. , Gallanis Gregory T. , Kallakury Bhaskar , Wellstein Anton , Riegel Anna T.
Published: April 2023

Adverse events related to palbociclib treatment
Supplement Figure 2 from Targeting Mitochondrial Proline Dehydrogenase with a Suicide Inhibitor to Exploit Synthetic Lethal Interactions with p53 Upregulation and Glutaminase Inhibition
Authors: Scott Gary K. , Yau Christina , Becker Beatrice C. , Khateeb Sana , Mahoney Sophia , Jensen Martin Borch , Hann Byron , Cowen Bryan J. , Pegan Scott D. , Benz Christopher C.
Published: April 2023

Supplement Figure 2. Mitochondria isolated from ZR-75-1 cells and assayed for PRODH activity by NADH induction to compare three propargyl- analogs with N-PPG for potential PRODH inhibitory activity.
Supplemental Figure 1 from Short- and Long-Term Effects of CDK4/6 Inhibition on Early-Stage Breast Cancer
Authors: Kietzman William B. , Graham Garrett T. , Ory Virginie , Sharif Ghada M. , Kushner Max H. , Gallanis Gregory T. , Kallakury Bhaskar , Wellstein Anton , Riegel Anna T.
Published: April 2023

Canonical effects of CDK4/6 inhibition
Supplementary Figures 1 through 5 from Intrapulmonary Delivery of CpG Microparticles Eliminates Lung Tumors
Authors: Sato Takashi , Shimosato Takeshi , Ueda Atsuhisa , Ishigatsubo Yoshiaki , Klinman Dennis M.
Published: April 2023

Supplementary Figure 1: Murine lung cancer model. Supplementary Figure 2: Release of CpG ODN from CpG-MP. Supplementary Figure 3: Effect of CpG-MP on survival of LLC challenged mice. Supplementary Figure 4: Effect of CpG-MP on immune cells in LLC tumor. Supplementary Figure 5: Correlation between cancer cell apoptosis and tumor infiltration by CTL vs immunosuppressive cells.
Supplementary Figure 5 - Low doses of Niraparib reduce the rate of DNA repair and sensitize cells to ionizing radiation from Poly-ADP-Ribose Polymerase as a Therapeutic Target in Pediatric Diffuse Intrinsic Pontine Glioma and Pediatric High-Grade Astrocytoma
Authors: Chornenkyy Yevgen , Agnihotri Sameer , Yu Man , Buczkowicz Pawel , Rakopoulos Patricia , Golbourn Brian , Garzia Livia , Siddaway Robert , Leung Stephie , Rutka James T. , Taylor Michael D. , Dirks Peter B. , Hawkins Cynthia
Published: April 2023

A, Several representative time points of SJG2 cells after immunofluorescent staining for γH2AX with DAPI as a counterstain after 1μM Niraparib, 2 Gy gamma radiation, or 2 Gy radiation pre-treated with 1μM Niraparib. Images were taken at indicated time points at 64X magnification.
Supplementary Figure 2 from Antitumor Activity and Acquired Resistance Mechanism of Dovitinib (TKI258) in RET-Rearranged Lung Adenocarcinoma
Authors: Kang Chan Woo , Jang Kang Won , Sohn Jinyoung , Kim Sung-Moo , Pyo Kyoung-Ho , Kim Hwan , Yun Mi Ran , Kang Han Na , Kim Hye Ryun , Lim Sun Min , Moon Yong Wha , Paik Soonmyung , Kim Dae Joon , Kim Joo Hang , Cho Byoung Chul
Published: April 2023

Supplementary Figure 2. Significant weight loss in LC-2/ad xenograft mice treated with vandetanib Mice bearing LC-2/ad cells were treated with vehicle only (Vehicle), dovitinib (DO 30mg/kg), dovitinib (DO 60mg/kg), or vandetanib (VA 50mg/kg) for 32days. Average percent change in body weight relative to initial body weight is shown. Error bars represent SEM **P < 0.001 for vehicle vs vandetanib 50mg/kg treatment group.
Table S3 from LncRNA CCAT1 Promotes Prostate Cancer Cell Proliferation by Interacting with DDX5 and MIR-28-5P
Authors: You Zonghao , Liu Chunhui , Wang Can , Ling Zhixin , Wang Yiduo , Wang Yali , Zhang Minghao , Chen Shuqiu , Xu Bin , Guan Han , Chen Ming
Published: April 2023

DDX5 peptides difference in desthiobiotinylated-CCAT1 sense vs antisense.
AC0010 supplementary methods and tables from AC0010, an Irreversible EGFR Inhibitor Selectively Targeting Mutated EGFR and Overcoming T790M-Induced Resistance in Animal Models and Lung Cancer Patients
Authors: Xu Xiao , Mao Long , Xu Wanhong , Tang Wei , Zhang Xiaoying , Xi Biao , Xu Rongda , Fang Xin , Liu Jia , Fang Ce , Zhao Li , Wang Xiaobo , Jiang Ji , Hu Pei , Zhao Hongyun , Zhang Li
Published: April 2023

AC0010 Supplementary methods; Table S1. IC50 values of AC0010 against representative kinases from biochemistry assay and cell-based ELISA assay; Table S2. List of 55 targets tested to assess the off target effect of AC0010 by an in vitro binding assay; Table S3. IC50 values of AC0010 in cell-based assays against targets with inhibition rate larger than 50% in binding assay; Table S4. Inhibitory activities of EGFR TKIs on proliferation of wild-type NCI-H1975, AC0010-resistant NCI-H1975-P1, NCI-H1975-AVR1 and Osimertinib-resistant NCI-H1975-OSR1 cells; Table S5. Inhibitory activities of AC0010 metabolites M7, MII-2 and MII-6 on proliferation of a panel of cell lines; Table S6. Inhibitory activities of AC0010 and its metabolites on IGF-1R in comparison with rociletinib and its metabolites; Table S7. Baseline demographic and clinical characteristics of 25 patients in dose escalation stage up to date
Figure s6 from LncRNA CCAT1 Promotes Prostate Cancer Cell Proliferation by Interacting with DDX5 and MIR-28-5P
Authors: You Zonghao , Liu Chunhui , Wang Can , Ling Zhixin , Wang Yiduo , Wang Yali , Zhang Minghao , Chen Shuqiu , Xu Bin , Guan Han , Chen Ming
Published: April 2023

The original western blot result.
AC0010 supplementary Figure 4 from AC0010, an Irreversible EGFR Inhibitor Selectively Targeting Mutated EGFR and Overcoming T790M-Induced Resistance in Animal Models and Lung Cancer Patients
Authors: Xu Xiao , Mao Long , Xu Wanhong , Tang Wei , Zhang Xiaoying , Xi Biao , Xu Rongda , Fang Xin , Liu Jia , Fang Ce , Zhao Li , Wang Xiaobo , Jiang Ji , Hu Pei , Zhao Hongyun , Zhang Li
Published: April 2023

AC0010 Supplementary Figure 4. The effects of AC0010 and gefitinib administration on rat skins
Figure S5 from LncRNA CCAT1 Promotes Prostate Cancer Cell Proliferation by Interacting with DDX5 and MIR-28-5P
Authors: You Zonghao , Liu Chunhui , Wang Can , Ling Zhixin , Wang Yiduo , Wang Yali , Zhang Minghao , Chen Shuqiu , Xu Bin , Guan Han , Chen Ming
Published: April 2023

Upregulation CCAT1 in LNCaP could promote UBE2C expression.
Figure S3 from LncRNA CCAT1 Promotes Prostate Cancer Cell Proliferation by Interacting with DDX5 and MIR-28-5P
Authors: You Zonghao , Liu Chunhui , Wang Can , Ling Zhixin , Wang Yiduo , Wang Yali , Zhang Minghao , Chen Shuqiu , Xu Bin , Guan Han , Chen Ming
Published: April 2023

CCAT1 promotes Du145 cell proliferation, colony formation, and cell cycle kinetics; and suppresses apoptosis .
Supplementary Data from Ceramide–Rubusoside Nanomicelles, a Potential Therapeutic Approach to Target Cancers Carrying p53 Missense Mutations
Authors: Khiste Sachin K. , Liu Zhijun , Roy Kartik R. , Uddin Mohammad B. , Hosain Salman B. , Gu Xin , Nazzal Sami , Hill Ronald A. , Liu Yong-Yu
Published: April 2023

Supplementary Figure S1-S3- supplementary S1: The stability of Cer-RUB nanomicelles; Supplementary Figure S2: Effects of Cer and CDDP on cell response; Supplementary Figure S3: Effects of treatments on body weights of mice bearing tumors. Supplementary Materials and Methods-Analysis of nanomicelle stability
Supplementary Figure S1 from Acquired Resistance to BET-PROTACs (Proteolysis-Targeting Chimeras) Caused by Genomic Alterations in Core Components of E3 Ligase Complexes
Authors: Zhang Lu , Riley-Gillis Bridget , Vijay Priyanka , Shen Yu
Published: April 2023

Establishment and characterization of the resistant cells
Supplementary Figure 1 from Anti–B-cell Maturation Antigen Chimeric Antigen Receptor T cell Function against Multiple Myeloma Is Enhanced in the Presence of Lenalidomide
Authors: Works Melissa , Soni Neha , Hauskins Collin , Sierra Catherine , Baturevych Alex , Jones Jon C. , Curtis Wendy , Carlson Patrick , Johnstone Timothy G. , Kugler David , Hause Ronald J. , Jiang Yue , Wimberly Lindsey , Clouser Christopher R. , Jessup Heidi K. , Sather Blythe , Salmon Ruth A. , Ports Michael O.
Published: April 2023

Supplementary Figure 1 shows information about the differential effects of lenalidomide with additional scfvs and the selected scfv at an additional E:T ratio with OPM-2 and RPMI-8226 cell lines
Supplementary Figure 1 from A Novel Fully Human Antibody targeting Extracellular Domain of PSMA Inhibits Tumor Growth in Prostate Cancer
Authors: Wu Jieheng , Han Donghui , Shi Shengjia , Zhang Qiang , Zheng Guoxu , Wei Ming , Han Yueheng , Li Guodong , Yang Fa , Jiao Dian , Xie Pin , Zhang Lingling , Yang An-Gang , Zhao Aizhi , Qin Weijun , Wen Weihong
Published: April 2023

This figure shows the amino acid sequence of the heavy and light chain of PSMAb antibody. CDR (Complementarity-determining region) sequences were underlined.
Supplementary Figure S2 from E7090, a Novel Selective Inhibitor of Fibroblast Growth Factor Receptors, Displays Potent Antitumor Activity and Prolongs Survival in Preclinical Models
Authors: Watanabe Miyano Saori , Yamamoto Yuji , Kodama Kotaro , Miyajima Yukiko , Mikamoto Masaki , Nakagawa Takayuki , Kuramochi Hiroko , Funasaka Setsuo , Nagao Satoshi , Sugi Naoko Hata , Okamoto Kiyoshi , Minoshima Yukinori , Nakatani Yusuke , Karoji Yuki , Ohashi Isao , Yamane Yoshinobu , Okada Toshimi , Matsushima Tomohiro , Matsui Junji , Iwata Masao , Uenaka Toshimitsu , Tsuruoka Akihiko
Published: April 2023

Inhibition of expression of proteins downstream of FGFR, including FRS2α, ERK, and AKT, in SNU-16 cells in vitro.
Supplementary Figure S1 from E7090, a Novel Selective Inhibitor of Fibroblast Growth Factor Receptors, Displays Potent Antitumor Activity and Prolongs Survival in Preclinical Models
Authors: Watanabe Miyano Saori , Yamamoto Yuji , Kodama Kotaro , Miyajima Yukiko , Mikamoto Masaki , Nakagawa Takayuki , Kuramochi Hiroko , Funasaka Setsuo , Nagao Satoshi , Sugi Naoko Hata , Okamoto Kiyoshi , Minoshima Yukinori , Nakatani Yusuke , Karoji Yuki , Ohashi Isao , Yamane Yoshinobu , Okada Toshimi , Matsushima Tomohiro , Matsui Junji , Iwata Masao , Uenaka Toshimitsu , Tsuruoka Akihiko
Published: April 2023

Kinome map of E7090. IC50 values of E7090 against wild-type kinases were used to create this kinome map. Illustration reproduced courtesy of Cell Signaling Technology, Inc. (www.cellsignal.com).
Figure S1 from PD-1/PD-L1 Immune Checkpoint Inhibition with Radiation in Bladder Cancer: In Situ and Abscopal Effects
Authors: Rompré-Brodeur Alexis , Shinde-Jadhav Surashri , Ayoub Mina , Piccirillo Ciriaco A. , Seuntjens Jan , Brimo Fadi , Mansure Jose Joao , Kassouf Wassim
Published: April 2023

Expression level of CTLA-4 at 24h-48h post radiation and expression levels of PD-L1 and CTLA-4 at experimental endpoint
Supplementary Table 1 from SHP2 Inhibition Overcomes RTK-Mediated Pathway Reactivation in KRAS-Mutant Tumors Treated with MEK Inhibitors
Authors: Lu Hengyu , Liu Chen , Velazquez Roberto , Wang Hongyun , Dunkl Lukas Manuel , Kazic-Legueux Malika , Haberkorn Anne , Billy Eric , Manchado Eusebio , Brachmann Saskia M. , Moody Susan E. , Engelman Jeffrey A. , Hammerman Peter S. , Caponigro Giordano , Mohseni Morvarid , Hao Huai-Xiang
Published: April 2023

A list of KRAS mutant cell lines in the study with lineages, zygosity determined by RNAseq, and percentages of p-MEK reduction by 5 micromolar SHP099 in the MEKi combination group.
Supplementary Figure 4 from SHP2 Inhibition Overcomes RTK-Mediated Pathway Reactivation in KRAS-Mutant Tumors Treated with MEK Inhibitors
Authors: Lu Hengyu , Liu Chen , Velazquez Roberto , Wang Hongyun , Dunkl Lukas Manuel , Kazic-Legueux Malika , Haberkorn Anne , Billy Eric , Manchado Eusebio , Brachmann Saskia M. , Moody Susan E. , Engelman Jeffrey A. , Hammerman Peter S. , Caponigro Giordano , Mohseni Morvarid , Hao Huai-Xiang
Published: April 2023

Evaluation of the in vivo combination benefit and the MAPK pathway suppression of MEK and SHP2 inhibitors in MIA PaCa-2 xenograft and a colon cancer PDX model.
Supplementary Figure 1 from The Novel Tubulin-Binding Checkpoint Activator BAL101553 Inhibits EB1-Dependent Migration and Invasion and Promotes Differentiation of Glioblastoma Stem-like Cells
Authors: Bergès Raphaël , Tchoghandjian Aurélie , Honoré Stéphane , Estève Marie-Anne , Figarella-Branger Dominique , Bachmann Felix , Lane Heidi A. , Braguer Diane
Published: April 2023

Chemical structure of BAL27862 and BAL101553
Supplementary Figure 1 from SHP2 Inhibition Overcomes RTK-Mediated Pathway Reactivation in KRAS-Mutant Tumors Treated with MEK Inhibitors
Authors: Lu Hengyu , Liu Chen , Velazquez Roberto , Wang Hongyun , Dunkl Lukas Manuel , Kazic-Legueux Malika , Haberkorn Anne , Billy Eric , Manchado Eusebio , Brachmann Saskia M. , Moody Susan E. , Engelman Jeffrey A. , Hammerman Peter S. , Caponigro Giordano , Mohseni Morvarid , Hao Huai-Xiang
Published: April 2023

Schematic illustration of MEKi-induced MAPK pathway feedback activation, SHP099 dose-dependent reduction of p-MEK induction by MEKi, and MEKi-induced p-AKT levels.
Effect of the complex on human fibroblast cell line. from Oncolytic Adenovirus Loaded with L-carnosine as Novel Strategy to Enhance the Antitumor Activity
Authors: Garofalo Mariangela , Iovine Barbara , Kuryk Lukasz , Capasso Cristian , Hirvinen Mari , Vitale Andrea , Yliperttula Marjo , Bevilacqua Maria Assunta , Cerullo Vincenzo
Published: April 2023

Most representative microscop photograph of human fibroblast cell line. (E) Cell viability was performed by MTS Assay on CCD- 112Sk cell line, in order to evaluate if complex affects negatively healthy cells. We have not observed toxic effect(incubation time 96 hrs) on fibroblast cultures, neither with complex nor virus alone and Carnosine6K alone (virus:100 VP/cell, Carnosine6K: 8mM).
Supplementary Figure 3 from Antibody-Based Delivery of Cytokine Payloads to Carbonic Anhydrase IX Leads to Cancer Cures in Immunocompetent Tumor-Bearing Mice
Authors: Ziffels Barbara , Stringhini Marco , Probst Philipp , Fugmann Tim , Sturm Theo , Neri Dario
Published: April 2023

a) In vitro immunohistochemistry of CAIX positive CT26 tumors. Tumors sections were stained with 10 Âµg/mL XE-mTNF, XE-hIL2 or XE-mIFNï�¡2. In vitro binding was detected with anti-mTNF, anti-hIL2 or anti-mIFNï�¡ï€²ï€ antibodies and AF488 labelled secondary antibodies (green). Blood vessels were stained with anti-CD31 and an AF594 labelled secondary antibody (red). b) Ex vivo immunofluorescence of human CAIX expressing CT26 tumor-bearing BALB/c mice. The mice received either 150 Âµg of XE-mIFNï�¡2, 50 Âµg of XE-hIL2, 3 Âµg of XE-mTNF and were sacrificed 24 hours after the injection. The tumor sections were stained with anti-mIFNï�¡ï€²ï€ antibody, anti-IL2 antibody or anti-TNF antibody and staining was detected using the Alexa Fluor{trade mark, serif} 488 Tyramide SuperBoost{trade mark, serif} Kit (Thermo Fisher). Nuclei are counterstained in blue. Scale bars represent 100 Âµm.
Supplementary Table 2 from Analysis of the Genomic Landscape in ALK+ NSCLC Patients Identifies Novel Aberrations Associated with Clinical Outcomes
Authors: Couëtoux du Tertre Mathilde , Marques Maud , Tremblay Lise , Bouchard Nicole , Diaconescu Razvan , Blais Normand , Couture Christian , Pelsser Vincent , Wang Hangjun , Higenell Valerie , Izzi Luisa , Gambaro Karen , Hoffert Cyrla , Srivastava Archana , Spatz Alan , Rousseau Caroline , McNamara Suzan , Cohen Victor , Batist Gerald , Agulnik Jason
Published: April 2023

Genomic coordinate for custom baits design hg19
Supplementary Figure 2 from Analysis of the Genomic Landscape in ALK+ NSCLC Patients Identifies Novel Aberrations Associated with Clinical Outcomes
Authors: Couëtoux du Tertre Mathilde , Marques Maud , Tremblay Lise , Bouchard Nicole , Diaconescu Razvan , Blais Normand , Couture Christian , Pelsser Vincent , Wang Hangjun , Higenell Valerie , Izzi Luisa , Gambaro Karen , Hoffert Cyrla , Srivastava Archana , Spatz Alan , Rousseau Caroline , McNamara Suzan , Cohen Victor , Batist Gerald , Agulnik Jason
Published: April 2023

ALK fusion identification and validation
Supplementary Figure 1 from Analysis of the Genomic Landscape in ALK+ NSCLC Patients Identifies Novel Aberrations Associated with Clinical Outcomes
Authors: Couëtoux du Tertre Mathilde , Marques Maud , Tremblay Lise , Bouchard Nicole , Diaconescu Razvan , Blais Normand , Couture Christian , Pelsser Vincent , Wang Hangjun , Higenell Valerie , Izzi Luisa , Gambaro Karen , Hoffert Cyrla , Srivastava Archana , Spatz Alan , Rousseau Caroline , McNamara Suzan , Cohen Victor , Batist Gerald , Agulnik Jason
Published: April 2023

Multivariate Cox analysis
Supplementary Figure S1 from Enhancing Therapeutic Efficacy of Oncolytic Herpes Simplex Virus-1 with Integrin β1 Blocking Antibody OS2966
Authors: Lee Tae Jin , Nair Mitra , Banasavadi-Siddegowda Yeshavanth , Liu Joseph , Nallanagulagari Tejaswini , Jaime-Ramirez Alena Cristina , Guo Jeffrey Yunhua , Quadri Haroon , Zhang Jianying , Bockhorst Kurt H. , Aghi Manish K. , Carbonell W. Shawn , Kaur Balveen , Yoo Ji Young
Published: April 2023

Supplementary Figure S1 shows that enhanced virus replication by combination treatment with oHSV and OS2966 significantly increases tumor necrosis in mammary fat-pad injected MDA468 tumor bearing mice.
Supplementary Tables 1 through 4 from A Phase I Study of the SMAC-Mimetic Birinapant in Adults with Refractory Solid Tumors or Lymphoma
Authors: Amaravadi Ravi K. , Schilder Russell J. , Martin Lainie P. , Levin Myron , Graham Martin A. , Weng David E. , Adjei Alex A.
Published: April 2023

Supplemental Table S1. Patient disposition Supplemental Table S2. M30 and M65 for cohorts with greatest number of patients Supplemental Table S3. m65 fragment for cohort 1-3 Supplemental Table S4. caspase measurements
Supplementary Figure S2 from MEN1309/OBT076, a First-In-Class Antibody–Drug Conjugate Targeting CD205 in Solid Tumors
Authors: Merlino Giuseppe , Fiascarelli Alessio , Bigioni Mario , Bressan Alessandro , Carrisi Corrado , Bellarosa Daniela , Salerno Massimiliano , Bugianesi Rossana , Manno Rosanna , Bernadó Morales Cristina , Arribas Joaquin , Bisht Arnima , Kaplan Angelo , Boyd Robert , Do Uyen T. , Swaminathan Sudha , Attanasio Nickolas , Lou San Lin , Dusek Rachel L. , Ackroyd James E. , Pham Phuoc Huy , Awdew Rahel , Aud Dee , Trang Michael , Lynch Carmel M. , Terrett Jonathan , Wilson Keith E. , Rohlff Christian , Manzini Stefano , Pellacani Andrea , Binaschi Monica
Published: April 2023

Supplementary Figure S2. In vitro characterization of MEN1309/OBT076. A) ELISA assay showed that both the unconjugated and DM4-conjugated antibodies were able to bind FcγRIIIA with the same affinity (n=2). B) FACS binding experiment on THP-1 cell line, performed by titrating unlabeled antibody with a constant amount of labelled antibody, showed high binding affinity of MBH1309/OBT076 to CD205 expressed on the cell surface with no affinity loss after conjugation (N=2). C) In vitro ADCC bioluminescence assay showed that, despite the ability to bind FcγRIIIA, MBH1309/OBT076 didn't induce any ADCC response. D) In vitro CDC assay on Raji cancer cell lines showed no CDC activity of MBH1309/OBT076 when incubated with purified human complement. On the contrary, Rituximab (used as positive control), showed a strong induction of CDC activity.
Supplementary Figures from Aurora A–Selective Inhibitor LY3295668 Leads to Dominant Mitotic Arrest, Apoptosis in Cancer Cells, and Shows Potent Preclinical Antitumor Efficacy
Authors: Du Jian , Yan Lei , Torres Raquel , Gong Xueqian , Bian Huimin , Marugán Carlos , Boehnke Karsten , Baquero Carmen , Hui Yu-Hua , Chapman Sonya C. , Yang Yanzhu , Zeng Yi , Bogner Sarah M. , Foreman Robert T. , Capen Andrew , Donoho Gregory P. , Van Horn Robert D. , Barnard Darlene S. , Dempsey Jack A. , Beckmann Richard P. , Marshall Mark S. , Chio Li-Chun , Qian Yuewei , Webster Yue W. , Aggarwal Amit , Chu Shaoyou , Bhattachar Shobha , Stancato Louis F. , Dowless Michele S. , Iversen Phillip W. , Manro Jason R. , Walgren Jennie L. , Halstead Bartley W. , Dieter Matthew Z. , Martinez Ricardo , Bhagwat Shripad V. , Kreklau Emiko L. , Lallena Maria Jose , Ye Xiang S. , Patel Bharvin K.R. , Reinhard Christoph , Plowman Gregory D. , Barda David A. , Henry James R. , Buchanan Sean G. , Campbell Robert M.
Published: April 2023

Supplementary Figures
Supplementary methods and materials and supplementary Tables S1-S3 from Acquired Resistance to EGFR TKIs Mediated by TGFβ1/Integrin β3 Signaling in EGFR-Mutant Lung Cancer
Authors: Wang Caiyun , Wang Tao , Lv Dacheng , Li Ling , Yue Jinnan , Chen Hong-Zhuan , Xu Lu
Published: April 2023

Supplementary methods and materials and supplementary tables show antibodies,primers and cell line characterization
Table S2 from TAS0728, A Covalent-binding, HER2-selective Kinase Inhibitor Shows Potent Antitumor Activity in Preclinical Models
Authors: Irie Hiroki , Ito Kimihiro , Fujioka Yayoi , Oguchi Kei , Fujioka Akio , Hashimoto Akihiro , Ohsawa Hirokazu , Tanaka Kenji , Funabashi Kaoru , Araki Hikari , Kawai Yuichi , Shimamura Tadashi , Wadhwa Renu , Ohkubo Shuichi , Matsuo Kenichi
Published: April 2023

The list of 68 non-kinase targets tested in a panel of binding assays
Figure S2 from TAS0728, A Covalent-binding, HER2-selective Kinase Inhibitor Shows Potent Antitumor Activity in Preclinical Models
Authors: Irie Hiroki , Ito Kimihiro , Fujioka Yayoi , Oguchi Kei , Fujioka Akio , Hashimoto Akihiro , Ohsawa Hirokazu , Tanaka Kenji , Funabashi Kaoru , Araki Hikari , Kawai Yuichi , Shimamura Tadashi , Wadhwa Renu , Ohkubo Shuichi , Matsuo Kenichi
Published: April 2023

Body weight changes in mice
Figure S2 from Dipyridamole Enhances the Cytotoxicities of Trametinib against Colon Cancer Cells through Combined Targeting of HMGCS1 and MEK Pathway
Authors: Zhou Sheng , Xu Huanji , Tang Qiulin , Xia Hongwei , Bi Feng
Published: April 2023

Simvastatin increased the expression of pERK through up-regulating the HMGCS1.
Supplementary Methods and Materials; Supplementary Figures S1-S4 from Tumor-Independent Host Secretomes Induced By Angiogenesis and Immune-Checkpoint Inhibitors
Authors: Mastri Michalis , Lee Christina R. , Tracz Amanda , Kerbel Robert S. , Dolan Melissa , Shi Yuhao , Ebos John M.L.
Published: April 2023

Supplementary Methods and Materials. Supplementary Figure S1: Differentially expressed genes from whole genome expression analysis after treatment with RTKIs or Abs. Supplementary Figure S2: Comparison of differentially expressed genes in cancer-free Balb/c mice treated for 7 days. Supplementary Figure S3: Quantification of select plasma proteins after 7-days treatment in cancer-free Balb/c mice. Supplementary Figure S4: Comparison of gene and protein expression changes in Balb/c mice after 7-day treatment with high dose Sunitinib (120mg/kg/day).
Table S1 from Single Agent and Synergistic Activity of the “First-in-Class” Dual PI3K/BRD4 Inhibitor SF1126 with Sorafenib in Hepatocellular Carcinoma
Authors: Singh Alok R. , Joshi Shweta , Burgoyne Adam M. , Sicklick Jason K. , Ikeda Sadakatsu , Kono Yuko , Garlich Joseph R. , Morales Guillermo A. , Durden Donald L.
Published: April 2023

Chau Talalay Synergy studies on HCC cells
Supplemental Table 3 from Mechanisms of Acquired Resistance to Trastuzumab Emtansine in Breast Cancer Cells
Authors: Li Guangmin , Guo Jun , Shen Ben-Quan , Yadav Daniela Bumbaca , Sliwkowski Mark X. , Crocker Lisa M. , Lacap Jennifer A. , Phillips Gail D. Lewis
Published: April 2023

Differentially expressed genes in T-DM1-resistant BT-474M1 cells with respect to the parental cell line (fold change > 2 fold and P < 0.05 of individual probes for a given gene in the microarray)
Supplemental Table 2 from Mechanisms of Acquired Resistance to Trastuzumab Emtansine in Breast Cancer Cells
Authors: Li Guangmin , Guo Jun , Shen Ben-Quan , Yadav Daniela Bumbaca , Sliwkowski Mark X. , Crocker Lisa M. , Lacap Jennifer A. , Phillips Gail D. Lewis
Published: April 2023

KPL-4 TR vs. Parental cells, gene expression changes > 5-fold
Supplementary Material and Methods from DNA Damage Response Inhibitor Combinations Exert Synergistic Antitumor Activity in Aggressive B-Cell Lymphomas
Authors: Restelli Valentina , Lupi Monica , Chilà Rosaria , Vagni Micaela , Tarantelli Chiara , Spriano Filippo , Gaudio Eugenio , Bertoni Francesco , Damia Giovanna , Carrassa Laura
Published: April 2023

Supplementary Material and Methods
Supplementary Figures 1-2 from ERBB2 Overexpression Establishes ERBB3-Dependent Hypersensitivity of Breast Cancer Cells to Withaferin A
Authors: Liu Wenjun , Barnette Annalise R. , Andreansky Samita , Landgraf Ralf
Published: April 2023

Supplementary Figure 1: After four hours of treatment with 10 μM WA, very low levels of ERBB2 in MD-MBA-231 are further reduced and drop below detection; Supplementary Figure 2: At 10 μM, the addition of WA to BT474 cells elicits a ligand-like response.
Table S2 from Distinct Transcriptional Programming Drive Response to MAPK Inhibition in BRAFV600-Mutant Melanoma Patient-Derived Xenografts
Authors: Feng Tianshu , Golji Javad , Li Ailing , Zhang Xiamei , Ruddy David A. , Rakiec Daniel P. , Geyer Felipe C. , Gu Jane , Gao Hui , Williams Juliet A. , Stuart Darrin D. , Meyer Matthew J.
Published: April 2023

Gene set enrichment results for the DEG clustering analysis using MSigDB and Metacore gene sets.
Figure S5 from Distinct Transcriptional Programming Drive Response to MAPK Inhibition in BRAFV600-Mutant Melanoma Patient-Derived Xenografts
Authors: Feng Tianshu , Golji Javad , Li Ailing , Zhang Xiamei , Ruddy David A. , Rakiec Daniel P. , Geyer Felipe C. , Gu Jane , Gao Hui , Williams Juliet A. , Stuart Darrin D. , Meyer Matthew J.
Published: April 2023

BRAFV600 mutant melanoma PDXs exhibit varied degrees of MAPK pathway suppression upon BRAF and MEK inhibitor treatment
Figure S1 from Distinct Transcriptional Programming Drive Response to MAPK Inhibition in BRAFV600-Mutant Melanoma Patient-Derived Xenografts
Authors: Feng Tianshu , Golji Javad , Li Ailing , Zhang Xiamei , Ruddy David A. , Rakiec Daniel P. , Geyer Felipe C. , Gu Jane , Gao Hui , Williams Juliet A. , Stuart Darrin D. , Meyer Matthew J.
Published: April 2023

Response to encorafenib and binimetinib of BRAFV600 mutant melanoma PDX models.
Supplementary Data from Assessing Metabolic Intervention with a Glutaminase Inhibitor in Real-Time by Hyperpolarized Magnetic Resonance in Acute Myeloid Leukemia
Authors: Zacharias Niki M. , Baran Natalia , Shanmugavelandy Sriram S. , Lee Jaehyuk , Lujan Juliana Velez , Dutta Prasanta , Millward Steven W. , Cai Tianyu , Wood Christopher G. , Piwnica-Worms David , Konopleva Marina , Bhattacharya Pratip K.
Published: April 2023

Figure S1-S4
Supplementary Table I and Supplementary Figure 1 from Targeting G-Quadruplex DNA Structures by EMICORON Has a Strong Antitumor Efficacy against Advanced Models of Human Colon Cancer
Authors: Porru Manuela , Artuso Simona , Salvati Erica , Bianco Armandodoriano , Franceschin Marco , Diodoro Maria Grazia , Passeri Daniela , Orlandi Augusto , Savorani Francesco , D'Incalci Maurizio , Biroccio Annamaria , Leonetti Carlo
Published: April 2023

Supplemental table I: Identification of optimal scheduling of EMICORON administration on HT29 xenografts. Supplemental Figure 1: NMR metabolomics on treated and untreated mice
Figure S2 from A Quinoline-Based DNA Methyltransferase Inhibitor as a Possible Adjuvant in Osteosarcoma Therapy
Authors: Manara Maria Cristina , Valente Sergio , Cristalli Camilla , Nicoletti Giordano , Landuzzi Lorena , Zwergel Clemens , Mazzone Roberta , Stazi Giulia , Arimondo Paola B. , Pasello Michela , Guerzoni Clara , Picci Piero , Nanni Patrizia , Lollini Pier-Luigi , Mai Antonello , Scotlandi Katia
Published: April 2023

Weight variations of Rag2 -/-;IL2rg -/- mice in single and combined treatments
Figure S7 from Inhibition of Autotaxin with GLPG1690 Increases the Efficacy of Radiotherapy and Chemotherapy in a Mouse Model of Breast Cancer
Authors: Tang Xiaoyun , Wuest Melinda , Benesch Matthew G.K. , Dufour Jennifer , Zhao YuanYuan , Curtis Jonathan M. , Monjardet Alain , Heckmann Bertrand , Murray David , Wuest Frank , Brindley David N.
Published: April 2023

Protein levels of cytokines in tumor adjacent adipose tissue with or without irradiation and/or GLPG1690. n = 5 in control, n = 6 in other groups.
Figure S3 from Lenalidomide Augments the Antitumor Activities of Eps8 Peptide-Specific Cytotoxic T Lymphocytes against Multiple Myeloma
Authors: Xie Xiaoling , Chen Yiran , Hu Yuxing , He Yanjie , Zhang Honghao , Li Yuhua
Published: April 2023

Analysis of the CD3+CD8+ T cells showed that Eps8cocktail-CTLs contained almost the same frequency of total T cells as Eps8cocktail@len-CTLs. All data represent the mean {plus minus} SD (n = 3).
Figure S3 from Inhibition of Autotaxin with GLPG1690 Increases the Efficacy of Radiotherapy and Chemotherapy in a Mouse Model of Breast Cancer
Authors: Tang Xiaoyun , Wuest Melinda , Benesch Matthew G.K. , Dufour Jennifer , Zhao YuanYuan , Curtis Jonathan M. , Monjardet Alain , Heckmann Bertrand , Murray David , Wuest Frank , Brindley David N.
Published: April 2023

H&E and immunohistochemistry staining for ATX and Bcl-2 in mouse breast tumor tissue. The border between tumor (red T) and stromal tissue (red S) is showed as red dash line. Scale bar = 100 mm.
Figure S1 from Inhibition of Autotaxin with GLPG1690 Increases the Efficacy of Radiotherapy and Chemotherapy in a Mouse Model of Breast Cancer
Authors: Tang Xiaoyun , Wuest Melinda , Benesch Matthew G.K. , Dufour Jennifer , Zhao YuanYuan , Curtis Jonathan M. , Monjardet Alain , Heckmann Bertrand , Murray David , Wuest Frank , Brindley David N.
Published: April 2023

Body weight of mice A: Body weight of mice before and after treatment with GLPG1690 in combination with radiation. n = 5 to 6 mice per group. B: Body weight of mice before and after treatment with GLPG1690 in combination with doxorubicin. n = 6 mice per group.
Supplementary Figure S7 from ERK Inhibitor LY3214996 Targets ERK Pathway–Driven Cancers: A Therapeutic Approach Toward Precision Medicine
Authors: Bhagwat Shripad V. , McMillen William T. , Cai Shufen , Zhao Baohui , Whitesell Matthew , Shen Weihua , Kindler Lisa , Flack Robert S. , Wu Wenjuan , Anderson Bryan , Zhai Yan , Yuan Xiu-Juan , Pogue Meghann , Van Horn Robert D. , Rao Xi , McCann Denis , Dropsey Andrew J. , Manro Jason , Walgren Jennie , Yuen Eunice , Rodriguez Michael J. , Plowman Gregory D. , Tiu Ramon V. , Joseph Sajan , Peng Sheng-Bin
Published: April 2023

In vivo effect of treatment on body weight loss.
Figure S3 from Targeting of BRM Sensitizes BRG1-Mutant Lung Cancer Cell Lines to Radiotherapy
Authors: Zernickel Erika , Sak Ali , Riaz Assad , Klein Diana , Groneberg Michael , Stuschke Martin
Published: April 2023

BRM knock-down has no effect on ɣ- H2AX or 53BP1 foci formation neither in BRG1 wild-type (A) nor BRG1-mutated (B) cell lines
Supplementary Figure S2 from ERK Inhibitor LY3214996 Targets ERK Pathway–Driven Cancers: A Therapeutic Approach Toward Precision Medicine
Authors: Bhagwat Shripad V. , McMillen William T. , Cai Shufen , Zhao Baohui , Whitesell Matthew , Shen Weihua , Kindler Lisa , Flack Robert S. , Wu Wenjuan , Anderson Bryan , Zhai Yan , Yuan Xiu-Juan , Pogue Meghann , Van Horn Robert D. , Rao Xi , McCann Denis , Dropsey Andrew J. , Manro Jason , Walgren Jennie , Yuen Eunice , Rodriguez Michael J. , Plowman Gregory D. , Tiu Ramon V. , Joseph Sajan , Peng Sheng-Bin
Published: April 2023

pan-RAF inhibitor can block increase in ERK phosphorylation due to inhibition of negative feedback on CRAF by ERK inhibitor.
Supplementary Figure S1 from ERK Inhibitor LY3214996 Targets ERK Pathway–Driven Cancers: A Therapeutic Approach Toward Precision Medicine
Authors: Bhagwat Shripad V. , McMillen William T. , Cai Shufen , Zhao Baohui , Whitesell Matthew , Shen Weihua , Kindler Lisa , Flack Robert S. , Wu Wenjuan , Anderson Bryan , Zhai Yan , Yuan Xiu-Juan , Pogue Meghann , Van Horn Robert D. , Rao Xi , McCann Denis , Dropsey Andrew J. , Manro Jason , Walgren Jennie , Yuen Eunice , Rodriguez Michael J. , Plowman Gregory D. , Tiu Ramon V. , Joseph Sajan , Peng Sheng-Bin
Published: April 2023

Time-dependent increase in apoptosis induction by LY3214996, pan-RAF inhibitor LY3009120 and MEK inhibitor trametinib in KRAS-mutant HCT116 colorectal cancer cells.
Supplementary Materials and Methods from Bispecific Antibodies and Antibody–Drug Conjugates (ADCs) Bridging HER2 and Prolactin Receptor Improve Efficacy of HER2 ADCs
Authors: Andreev Julian , Thambi Nithya , Perez Bay Andres E. , Delfino Frank , Martin Joel , Kelly Marcus P. , Kirshner Jessica R. , Rafique Ashique , Kunz Arthur , Nittoli Thomas , MacDonald Douglas , Daly Christopher , Olson William , Thurston Gavin
Published: April 2023

Supplementary Materials and Methods
Figure S3 from Macrophage Susceptibility to Emactuzumab (RG7155) Treatment
Authors: Pradel Leon P. , Ooi Chia-Huey , Romagnoli Solange , Cannarile Michael A. , Sade Hadassah , Rüttinger Dominik , Ries Carola H.
Published: April 2023

Confirmation of sIL-4RÎ± binding to IL-4 via SPR; Figure S4. Gene expression profiling of in vitro differentiated MÏ† for a selection of cytokine receptors
Supplementary Fig.4 from Nuclear Export of Ubiquitinated Proteins Determines the Sensitivity of Colorectal Cancer to Proteasome Inhibitor
Authors: Wu Tingyu , Chen Wei , Zhong Yongwang , Hou Xiaodan , Fang Shengyun , Liu Chen-Ying , Wang Guanghui , Yu Tong , Huang Yu-Yang , Ouyang Xuesong , Li Henry Q.X. , Cui Long , Yang Yili
Published: April 2023

Nuclear p53 plays a critical role in synergistic cytotoxic effect in RKO cells.
Supplementary Figure S3 from PAXIP1 Potentiates the Combination of WEE1 Inhibitor AZD1775 and Platinum Agents in Lung Cancer
Authors: Jhuraney Ankita , Woods Nicholas T. , Wright Gabriela , Rix Lily , Kinose Fumi , Kroeger Jodi L. , Remily-Wood Elizabeth , Cress W. Douglas , Koomen John M. , Brantley Stephen G. , Gray Jhanelle E. , Haura Eric B. , Rix Uwe , Monteiro Alvaro N.
Published: April 2023

(A) WEE1 In vitro kinase assays. Purified GST-tagged WEE1 and active GST-CDK1 were incubated in the presence or absence of recombinant GST-PAXIP1 tBRCT C2. Arrows indicate the bands for auto-phosphorylated WEE1 and phosphorylated CDK1. Note the absence of a phosphorylated band corresponding to the expected size of the recombinant PAXIP1 tBRCT C2. (B) Experimental design timeline for cell cycle assays. (C-F) H322 cells transfected with: (C) empty vector; a vector expressing PAXIP1 (D); a vector containing a scrambled control shRNA (E) or PAXIP1 shRNA (F) were mock-treated or pre-treated with AZD1775 for 1 h prior to receiving 6 Gy of IR. Cells were incubated for 4 hours and cell cycle analysis was performed to test the mitotic index (percentage of phospho-histone H3 positive cells) at the early G2/M checkpoint post IR.
Supplementary table 2. from In Silico Analysis Guides Selection of BET Inhibitors for Triple-Negative Breast Cancer Treatment
Authors: Pérez-Peña Javier , Serrano-Heras Gemma , Montero Juan Carlos , Corrales-Sánchez Verónica , Pandiella Atanasio , Ocaña Alberto
Published: April 2023

Functional analyses of upregulated genes with a >4 fold changed. Specific functional categories were assigned by DAVID Bioinformatics Resources 6.7. Table 2 shows modified functions at 12 hours and table 3 at 24 hours.
Supplementary table 1. from In Silico Analysis Guides Selection of BET Inhibitors for Triple-Negative Breast Cancer Treatment
Authors: Pérez-Peña Javier , Serrano-Heras Gemma , Montero Juan Carlos , Corrales-Sánchez Verónica , Pandiella Atanasio , Ocaña Alberto
Published: April 2023

List of genes that codify for TFs with a >4 fold change; comparing normal breast with basal-like tumors. Gene expression analyses is described in "Material and methods".
Supplementary figure 3 from In Silico Analysis Guides Selection of BET Inhibitors for Triple-Negative Breast Cancer Treatment
Authors: Pérez-Peña Javier , Serrano-Heras Gemma , Montero Juan Carlos , Corrales-Sánchez Verónica , Pandiella Atanasio , Ocaña Alberto
Published: April 2023

Knockdown of LM04, DEPDC and FOXM1 and their effect of proliferation at 72 hours after infection, measured using MTT assays, (A, B and C, respectively), as described in "Material and methods". For LM04, results for two constructions are shown.
Supplementary figure 2 from In Silico Analysis Guides Selection of BET Inhibitors for Triple-Negative Breast Cancer Treatment
Authors: Pérez-Peña Javier , Serrano-Heras Gemma , Montero Juan Carlos , Corrales-Sánchez Verónica , Pandiella Atanasio , Ocaña Alberto
Published: April 2023

Effect on proliferation of JQ1 at doses below 300nM at 3 days (upper panel) and at 6 days (lower panel), measured using MTT assay in a panel of four different triple negative cell lines, as described in "Material and methods".
Supplementary Figures 1-6 and Tables 1-2 from Entrectinib, a Pan–TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications
Authors: Ardini Elena , Menichincheri Maria , Banfi Patrizia , Bosotti Roberta , De Ponti Cristina , Pulci Romana , Ballinari Dario , Ciomei Marina , Texido Gemma , Degrassi Anna , Avanzi Nilla , Amboldi Nadia , Saccardo Maria Beatrice , Casero Daniele , Orsini Paolo , Bandiera Tiziano , Mologni Luca , Anderson David , Wei Ge , Harris Jason , Vernier Jean-Michel , Li Gang , Felder Eduard , Donati Daniele , Isacchi Antonella , Pesenti Enrico , Magnaghi Paola , Galvani Arturo
Published: April 2023

Supplementary Figure 1. Efficacy of entrectinib on KM12 xenograft model using the scheduling 4 days on/ 3 days off. Supplementary Figure 2. Mechanism of action of entrectinib compared to crizotinib in ALK-dependent Ba/F3 cells. Supplementary Figure 3. Cell cycle distrivbution of Karpas-299 and SR-786 cells treated with entrectinib for different periods of time Supplementary Figure 4. Mechanism of action studies of entrectinib in additional ALK-dependent ALCL models Supplementary Figure 5. In vivo efficacy of entrectinib on NCI-H2228 xenograft model using the scheduling 4 days on/ 3 days off Supplementary Figure 6. Representative magnetic resonance images of mice bearing intracranial tumors treated with vehicle, entrectinib or crizotinib Supplementary Table 1. List of human tumor cell lines treated with entrectinib Supplementary Table 2. Pharmacokinetic paramenters of entrectinib evaluated after repeated administration of compound in CD1 mice.
Figure S3 from A Small-Molecule Inhibitor of WEE1, AZD1775, Synergizes with Olaparib by Impairing Homologous Recombination and Enhancing DNA Damage and Apoptosis in Acute Leukemia
Authors: Garcia Tamara B. , Snedeker Jonathan C. , Baturin Dmitry , Gardner Lori , Fosmire Susan P. , Zhou Chengjing , Jordan Craig T. , Venkataraman Sujatha , Vibhakar Rajeev , Porter Christopher C.
Published: April 2023

Inhibition of endogenous P53 in OCI-AML3 cells does not enhance the combinatorial activity of AZD1775 and olaparib. A-C. OCI-AML3 parental (A), MiG (B), and MiG-DDp53 (C) cells were treated with DMSO (vehicle control), olaparib (2 uM), and/or AZD1775 (200 nM) for 72 hr. Viable cell counts are normalized to cells receiving no treatment (NT). Results are shown as mean {plus minus} SEM from three independent experiments. *, P < 0.05. **, P < 0.01. ***, P < 0.001.
Supplemental Table 5 from Sensitizing Triple-Negative Breast Cancer to PI3K Inhibition by Cotargeting IGF1R
Authors: de Lint Klaas , Poell Jos B. , Soueidan Hayssam , Jastrzebski Katarzyna , Vidal Rodriguez Jordi , Lieftink Cor , Wessels Lodewyk F.A. , Beijersbergen Roderick L.
Published: April 2023

Manually curated set of IGF1R- and PI3K-related genes